Current and emerging medications for overweight or obesity in people with comorbidities
Author:
Open Access
- 8 July 2015
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (11) , 1021-1032
Abstract
Recently, the recognition of obesity as a complex disease that requires chronic management has become more widespread. There has also been a movement away from a focus on body mass index alone, and toward the management of obesity‐related comorbidities as well as excess weight. This article examines the current and emerging pharmacological options for weight management in people with overweight or obesity who have, or are at a high risk of, weight‐related comorbidities. In the USA , the current options for pharmacological weight management are phentermine (indicated for short‐term use only), orlistat, combined phentermine/topiramate extended release, lorcaserin, naltrexone/bupropion and liraglutide 3.0 mg. Currently, orlistat, naltrexone/bupropion and liraglutide 3.0 mg are approved in E urope. All of the above‐mentioned medications have shown weight‐loss efficacy versus placebo. Those approved for long‐term weight management have also been associated with improvements in weight‐related comorbidities, such as hypertension, prediabetes, diabetes or dyslipidaemia, or related biomarkers. As with all drugs, the safety and tolerability profiles of medications for weight management should be considered alongside their efficacy to ensure correct use. Additional medications for weight management that are in clinical development include bupropion/zonisamide and beloranib. The field of obesity treatment is advancing with a number of medications being recently approved, and with other pharmacological options emerging.Keywords
Funding Information
- Eisai
- Novo Nordisk
- Newton Public Schools, City of Newton
- Shire
This publication has 62 references indexed in Scilit:
- Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trialDiabetes, Obesity and Metabolism, 2015
- Obesity and polycystic ovary syndrome2015
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trialsJournal of Diabetes and its Complications, 2014
- Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013
- Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposityDiabetes, Obesity and Metabolism, 2013
- Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index CategoriesJAMA, 2013
- Pragmatic study of orlistat 60 mg on abdominal obesityEuropean Journal of Clinical Nutrition, 2011
- High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish populationBMC Public Health, 2008
- Metformin and body weightInternational Journal of Obesity, 2007